About Bruker Microbiology & Diagnostics
More than a decade ago, Bruker changed microbiology by developing the MALDI Biotyper®, the market-leading MALDI-TOF system for fast identification of more than 4,350 microorganisms from culture, including 182 of the currently known 201 mycobacteria species. With regards to assay innovations, Bruker Molecular Diagnostics offers a comprehensive PCR diagnostics portfolio for tuberculosis and nontuberculous mycobacteria; the portfolio is unique as it encompasses the only leprosy molecular diagnostic test focusing on resistance in the market. Other highlights include that the portfolio enables M. tuberculosis complex detection, which is also possible in combination with rifampicin and isoniazid resistance identification and differentiation of nontuberculous mycobacteria. The product range has recently been expanded with the FluoroType®Mycobacteria VER 1.0 assay, a semi-automated qualitative in vitro test for the detection and differentiation of 32 clinically relevant nontuberculous mycobacteria and the detection of M. tuberculosis complex from cultured material, in one well. The assay is powered by Bruker’s pioneering LiquidArray®technology, which enables high level multiplexing.